Barclays
TARS icon

Barclays’s Tarsus Pharmaceuticals TARS Stock Holding History

Barclays’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,700
Closed -$755K – 5673
2025
Q3 		$755K Buy
+12,700
New +$625K ﹤0.01% 3539

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's TARS Position: Q2 2026 in Review

Barclays increased its Tarsus Pharmaceuticals (TARS) stake by 31% in Q2 2026, buying an estimated $553K and bringing the position to 36,658 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2257.

Barclays first reported a position in TARS in Q1 2022 and has held it in 18 quarters since. The position peaked at $6.61M in Q4 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Barclays held 36,658 shares of Tarsus Pharmaceuticals worth $2.31M as of Q2 2026.
  • Barclays bought 8,654 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $553K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2257 holding.
  • Barclays first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Tarsus Pharmaceuticals position peaked at $6.61M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.